Methods to Help People Stop Vaping

ARB's work on this review has been supported by Cancer Research UK Project Award funding. This is not deemed a conflict of interest. NL has received payment for lectures on systematic review methodology (Oxford University Hospitals NHS Foundation Trust), and has been an applicant and principal investigator on project funding to carry out research in the area of tobacco control from the NIHR Evidence Synthesis programme, Cancer Research UK (charity), Clarion Futures (charity), Oxfordshire County Council and the NIHR Oxfordshire and Thames Valley ARC, and Greater Manchester NHS Integrated Care. None of this is deemed a conflict of interest. JLB was employed by the University of Oxford to work as a Managing Editor and Information Specialist for the Cochrane Tobacco Addiction Group before becoming an author on this review. During this time, he was involved in the editorial processing of the review. He is now an Editor for Cochrane. Since becoming an author, he has not been involved in the editorial process for this review. Core infrastructure funding for the Cochrane Tobacco Addiction Group was provided by the National Institute for Health and Care Research (NIHR) to the University of Oxford. CN has received an honorarium from Vox Media for filming a 'nicotine explainer' on the role of nicotine in addiction. This is not deemed a conflict of interest. CN is a member of the advisory council for 'Action on Smoking and Health (ASH)'. CN is lead author of the Cochrane review of incentives for smoking cessation. TT has no known conflicts of interest. TT is a Cochrane editor, but was not involved in the editorial process for this review. NAR has received royalties from UpToDate, Inc., for chapters on electronic cigarettes and occasional fees from academic hospitals or professional medical societies for lectures on smoking cessation that include discussion of electronic cigarettes. NAR was a member of the committee that produced the 2018 National Academies of Science, Engineering, and Medicine's Consensus Study Report on the Public Health Benefits of E‐cigarettes. She was unpaid for this work. NAR is employed by Massachusetts General Hospital (MGH). Outside the topic of e‐cigarettes, NAR previously consulted for Achieve LifeSciences, which is developing an investigational smoking cessation medication for US Food and Drug Administration (FDA) approval (cytisine), and her institution (MGH) receives a grant from the company as a site for a clinical trial testing the safety and efficacy of cytisine for smoking and vaping cessation. NAR holds grants from the National Institutes of Health (NIH) for other research work. TRF receives funding from the NIHR Community Healthcare MedTech and In Vitro Diagnostics Co‐operative at Oxford Health NHS Foundation Trust (MIC‐2016‐018) and the NIHR Applied Research Collaboration Oxford and Thames Valley at Oxford Health NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the National Institute for Health and Care Research (NIHR), or the Department of Health and Social Care. LD has received grants from the National Institute of Health Research (NIHR) Public Health Research (PHR) September 2021 to August 2024, and the Medical Research Council (MRC) Public Health Intervention Development Scheme (PHIND) March 2021 to May 2022. LD has received consulting fees from and acted as an Advisory Board Member for the development of smoking cessation resources for Nicorette UK, Johnson & Johnson. LD's other/non‐financial interest: interviewee for TV.net Latvia: one‐hour programme on e‐cigarettes 23 February 2023. LD has an affiliation to the following organisations that have a declared opinion or position on the topic: Action on Smoking and Health (ASH) (Advisory Council Member); Drug Science (Member of the Scientific Committee). Other: Invited Speaker: All Party Parliamentary Group (APPG) on vaping 19 April 2023. RB holds a National Institute for Health Research (NIHR) grant, but this did not directly fund this current work. ADW's work on this review has been supported by Cancer Research UK Project Award funding. This is not deemed a conflict of interest. LB is funded through the NIHR Policy Research Unit in Addictions. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. MC's work is supported by Cancer Research UK (charity). She is a Cochrane Proposal Editor, but was not involved in the editorial process for this review. None of this was deemed a conflict of interest. ES is funded through the NIHR Policy Research Unit in Addictions. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. JHB has received payment for consulting from the Truth Initiative, and payment for board membership from the US Food and Drug Administration. She has received funding (to her institution) to carry out research in the area of tobacco control from the NIHR Evidence Synthesis programme, Cancer Research UK (charity), and the National Institutes of Health and US Food and Drug Administration. She is a member of Health Canada's Scientific Advisory Board for Vaping Products. None of this is deemed a conflict of interest.